146 related articles for article (PubMed ID: 23488610)
1. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
Brander D; Rizzieri D; Gockerman J; Diehl L; Shea TC; Decastro C; Moore JO; Beaven A
Leuk Lymphoma; 2013 Dec; 54(12):2627-30. PubMed ID: 23488610
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
[TBL] [Abstract][Full Text] [Related]
3. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG
Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
[TBL] [Abstract][Full Text] [Related]
7. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Jahan T; Gu L; Kratzke R; Dudek A; Otterson GA; Wang X; Green M; Vokes EE; Kindler HL
Lung Cancer; 2012 Jun; 76(3):393-6. PubMed ID: 22197613
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
[TBL] [Abstract][Full Text] [Related]
9. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
10. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
[TBL] [Abstract][Full Text] [Related]
11. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice.
Zips D; Hessel F; Krause M; Schiefer Y; Hoinkis C; Thames HD; Haberey M; Baumann M
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):908-14. PubMed ID: 15708274
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Gerstner ER; Eichler AF; Plotkin SR; Drappatz J; Doyle CL; Xu L; Duda DG; Wen PY; Jain RK; Batchelor TT
J Neurooncol; 2011 Jun; 103(2):325-32. PubMed ID: 20821342
[TBL] [Abstract][Full Text] [Related]
15. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
Sharma S; Freeman B; Turner J; Symanowski J; Manno P; Berg W; Vogelzang N
Invest New Drugs; 2009 Feb; 27(1):63-5. PubMed ID: 18641920
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Gauler TC; Besse B; Mauguen A; Meric JB; Gounant V; Fischer B; Overbeck TR; Krissel H; Laurent D; Tiainen M; Commo F; Soria JC; Eberhardt WEE
Ann Oncol; 2012 Mar; 23(3):678-687. PubMed ID: 21617019
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Hecht JR; Trarbach T; Hainsworth JD; Major P; Jäger E; Wolff RA; Lloyd-Salvant K; Bodoky G; Pendergrass K; Berg W; Chen BL; Jalava T; Meinhardt G; Laurent D; Lebwohl D; Kerr D
J Clin Oncol; 2011 May; 29(15):1997-2003. PubMed ID: 21464406
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
